179 related articles for article (PubMed ID: 6508821)
61. A novel mechanism for resistance to the antimetabolite N-phosphonoacetyl-L-aspartate by Helicobacter pylori.
Burns BP; Mendz GL; Hazell SL
J Bacteriol; 1998 Nov; 180(21):5574-9. PubMed ID: 9791105
[TBL] [Abstract][Full Text] [Related]
62. Measurement of aspartate carbamoyltransferase activity by high performance liquid chromatography.
Grem JL; Drake JC; Allegra CJ
Anticancer Drugs; 1993 Oct; 4(5):545-54. PubMed ID: 8292811
[TBL] [Abstract][Full Text] [Related]
63. X-ray scattering titration of the quaternary structure transition of aspartate transcarbamylase with a bisubstrate analogue: influence of nucleotide effectors.
Fetler L; Tauc P; Hervé G; Moody MF; Vachette P
J Mol Biol; 1995 Aug; 251(2):243-55. PubMed ID: 7643401
[TBL] [Abstract][Full Text] [Related]
64. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Grant S; Rauscher F; Cadman E
Cancer Res; 1982 Oct; 42(10):4007-13. PubMed ID: 6955007
[TBL] [Abstract][Full Text] [Related]
65. Regulatory behavior of Escherichia coli aspartate transcarbamylase altered by site-specific mutation of Tyr240----Phe in the catalytic chain.
Wedler FC; Hsuanyu YC; Kantrowitz ER; Middleton SA
J Biol Chem; 1989 Oct; 264(29):17266-74. PubMed ID: 2677002
[TBL] [Abstract][Full Text] [Related]
66. The role of low-dose PALA in biochemical modulation.
O'Dwyer PJ
Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
[TBL] [Abstract][Full Text] [Related]
67. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
[TBL] [Abstract][Full Text] [Related]
68. Comparison of van 't Hoff and calorimetrically determined enthalpies of binding of N-phosphonacetyl-L-aspartate to E. coli aspartate transcarbamylase.
Hofmann GE; Knier BL; Allewell NM
Biophys Chem; 1979 Jul; 10(1):47-54. PubMed ID: 385074
[TBL] [Abstract][Full Text] [Related]
69. Carrot cells detoxify N-phosphonoacetyl-L-aspartate by esterification.
Cole SC; Yon RJ
Biochem J; 1988 Nov; 255(3):813-6. PubMed ID: 3214426
[TBL] [Abstract][Full Text] [Related]
70. Replacement of Asp-162 by Ala prevents the cooperative transition by the substrates while enhancing the effect of the allosteric activator ATP on E. coli aspartate transcarbamoylase.
Fetler L; Tauc P; Baker DP; Macol CP; Kantrowitz ER; Vachette P
Protein Sci; 2002 May; 11(5):1074-81. PubMed ID: 11967364
[TBL] [Abstract][Full Text] [Related]
71. Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles.
Poupon MF; Smith KA; Chernova OB; Gilbert C; Stark GR
Mol Biol Cell; 1996 Mar; 7(3):345-54. PubMed ID: 8868464
[TBL] [Abstract][Full Text] [Related]
72. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
Roboz J; Suzuki R; Rose E
J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
[TBL] [Abstract][Full Text] [Related]
73. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
74. Dose-dependent inhibition of aspartate carbamoyltransferase in peripheral blood mononuclear cells in patients receiving N-(phosphonacetyl)-L-aspartate.
Grem JL; McAtee N; Drake JC; Steinberg S; Allegra CJ
Adv Exp Med Biol; 1993; 339():119-23. PubMed ID: 8178710
[TBL] [Abstract][Full Text] [Related]
75. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
76. Ligation alters the pathway of urea-induced denaturation of the catalytic trimer of Escherichia coli aspartate transcarbamylase.
Bromberg S; LiCata VJ; Mallikarachchi D; Allewell NM
Protein Sci; 1994 Aug; 3(8):1236-44. PubMed ID: 7987218
[TBL] [Abstract][Full Text] [Related]
77. Protein alterations associated with gene amplification in cultured human and rodent cells.
Conner EA; Wirth PJ
Electrophoresis; 1996 Jul; 17(7):1257-64. PubMed ID: 8855414
[TBL] [Abstract][Full Text] [Related]
78. Quaternary structure changes in aspartate transcarbamylase studied by X-ray solution scattering. Signal transmission following effector binding.
Hervé G; Moody MF; Tauc P; Vachette P; Jones PT
J Mol Biol; 1985 Sep; 185(1):189-99. PubMed ID: 3900420
[TBL] [Abstract][Full Text] [Related]
79. In situ behavior of the pyrimidine pathway enzymes in Saccharomyces cerevisiae. I. Catalytic and regulatory properties of aspartate transcarbamylase.
Penverne B; Hervé G
Arch Biochem Biophys; 1983 Sep; 225(2):562-75. PubMed ID: 6354093
[TBL] [Abstract][Full Text] [Related]
80. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
Chan TC; Markman M; Cleary S; Howell SB
Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
